Tuberculosis (TB) is one of the most infectious diseases in the current scenario, triggered when the body
detects Mycobacterium tuberculosis. Since tuberculosis is a communicable disease or transferable disease, it is easily transmitted
via the inhalation cycle of air droplets carrying the particular bacteria to another person who remains in contact with the
infected person. The in silico study was conducted with the help of molecular docking to treat tuberculosis to inhibit the activity
of DrpE1 by drug molecule.
Methods: All the studies were based on docking with molecules. Docking was done with the aid of docking software between all
the ligands and the target protein DrpE1 (PDB ID: 4FDN). We picked several natural compounds, such as Thiophenes,
Sulfonamides, Benzimidazole, Lidamycin and protein target as DrpE1 (PDB ID: 4FDN). After Biovia Discovery Studio
Visualizer 's protein preparation we imported all of the ligand for virtual screening into PyRx software. Benzimidazole was the
strongest compound again
